Clinical trial
Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.
NCT04817618 · Novartis Pharmaceuticals, Industry · Recruiting
Key facts
| NCT number | NCT04817618 |
|---|---|
| Title | Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy. |
| Official title | A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Iptacopan (LNP023) in Complement 3 Glomerulopathy. |
| Acronym | APPEAR-C3G |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Recruiting |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | C3G |
| Intervention type | Drug |
| Interventions | Placebo, iptacopan |
| Enrollment | 98 |
| Start date | Jul 28, 2021 |
| Primary completion | Mar 27, 2026 |
| Completion | Jul 4, 2026 |
| First posted | Mar 26, 2021 |
| Last update posted | Mar 4, 2025 |
| Countries | Argentina, Belgium, Brazil, Canada, China, Czechia, France, Germany, Greece, India, Israel, Italy and 7 more |
At a glance
- 10–99 Study sites
- No Results posted
- 1–9 FDA inspections linked to this trial
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: